Cited by 526Systemic Lupus Erythematosus ResearchBlood Coagulation and Thrombosis MechanismsAcute Ischemic Stroke Management

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Anticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous Thrombosis

Ginsburg, Katherine S., Liang, Matthew H., Newcomer, Laura, Goldhaber, Samuel Z., Schur, Peter H., Hennekens, Charles H., Stampfer, Meir J.·1992·Annals of Internal Medicine

DOI 10.7326/0003-4819-117-12-997

Open this paper in CoChat — free account

Abstract

Objective To determine whether the presence of anticardiolipin antibodies is a risk factor for ischemic stroke and venous thrombosis in healthy adult men. Design A nested, case-control study in a prospective cohort. Setting A nationwide study of physicians. Participants The study sample was drawn from the Physicians' Health Study, a randomized, double-blind, placebo-controlled trial of aspirin and beta-carotene in 22,071 male physicians. At entry, 68% of the participants submitted plasma samples that were subsequently frozen at -80 degrees C. During 60.2 months of follow-up, follow-up for nonfatal outcomes was 99.7% complete and ascertainment of fatal outcomes was 100% complete. We identified men with documented ischemic stroke, deep venous thrombosis of the leg, or pulmonary embolus and for whom a plasma sample was available. A control was matched by age, smoking history, and length of follow-up to each of the 100 patients with ischemic stroke and the 90 patients with deep venous thrombosis or pulmonary embolus. Measurements Plasma samples were assessed for IgG anticardiolipin antibodies by enzyme-linked immunosorbent assay. The mean anticardiolipin antibody titers of the case patients in the two diagnostic groups (ischemic stroke; venous thrombosis or pulmonary embolus) were compared with those of the control groups, and relative risks were calculated for patients in increasing percentile categories of anticardiolipin antibodies by conditional logistic regression. Results T…

Integrity signals

Registry

Crossref · 10.7326/0003-4819-117-12-997

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).
McNeil, H. P., Simpson, R. J., Chesterman, C. N., & Krilis, S. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4120 · Cited by 1,595
Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus
Harris, E. N., Boey, M. L., Mackworth-Young, C. G., Gharavi, A. E., Patel, B. M., Loizou, S., & Hughes, G. R. V. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91267-9 · Cited by 1,383
Antiphospholipid Antibodies: Anticardiolipin and the Lupus Anticoagulant in Systemic Lupus Erythematosus (SLE) and in Non-SLE Disorders
Love, P. E., & Santoro, S. A. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-9-682 · Cited by 1,095
The “Primary” Antiphospholipid Syndrome
Asherson, R. A., Khamashta, M. A., Ordi, J., Derksen, R. H. W. M., Machin, S. J., Barquinero, J., OUTT, H. H., Harris, E. N., Vilardell, M., & Hughes, G. R. V. (1989) · Medicine · doi:10.1097/00005792-198911000-00004 · Cited by 963
The "primary" antiphospholipid syndrome: major clinical and serological features.
Asherson, R. A., Khamashta, M. A., Ordi‐Ros, J., Derksen, R. H. W. M., Machin, S. J., Barquinero, J., OUTT, H. H., Harris, E. N., Vilardell, M., & Hughes, G. R. V. (1989) · PubMed · Cited by 892
Antiphospholipid Antibodies and the Antiphospholipid Syndrome in Systemic Lupus Erythematosus A Prospective Analysis of 500 Consecutive Patients
Alarcón-Segovia, D., Delezé, M., Oria, C. V., Sánchez‐Guerrero, J., Gómez-Pacheco, L., Cabiedes, J., Fernández, L. A. N., & de León, S. P. (1989) · Medicine · doi:10.1097/00005792-198911000-00003 · Cited by 635
ARTERIAL THROMBOSIS, INTRAUTERINE DEATH AND "LUPUS" ANTICOAGULANT: DETECTION OF IMMUNOGLOBULIN INTERFERING WITH PROSTACYCLIN FORMATION
Carreras, L., Machin, S. J., Deman, R., DEFREYN, G., Vermylen, J., Spitz, B., & Assche, A. V. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92087-0 · Cited by 551
Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results.
Loizou, S., McCrea, J. D., Rudge, A. C., Reynolds, R., Boyle, C. C., & Harris, E. N. (1985) · PubMed Central · Cited by 549
Thrombosis, Recurrent Fetal Loss, and Thrombocytopenia
Harris, E. N. (1986) · Archives of Internal Medicine · doi:10.1001/archinte.1986.00360230069012 · Cited by 546
Preliminary Report: Findings from the Aspirin Component of the Ongoing Physicians' Health Study
The Steering Committee of the Physicians' Health Study Research Group (1988) · New England Journal of Medicine · doi:10.1056/nejm198801283180431 · Cited by 522

Show all 49 references

Research works printed but not linked: 15

Meyer O, 1987, J Rheum., 14, 502
Colaco C, 1983, Ann Rheum Dis., 42, 228
Harris E, 1985, J Clin Lab Immunol., 16, 1
Colaco C, 1985, Clin Exp Immunol., 59, 449
Harris E, 1987, Clin Exp Immunol., 68, 215
Hall S, 1984, J Rheum., 11, 846
Asherson R, 1989, Q J Med., 73, 1103
Cronin M, 1988, J Rheum., 15, 795
Klemp P, 1988, Clin Exp Immunol., 74, 254
Lavalle C, 1990, J Rheum., 17, 34
Coon W, 1976, Surg Gynecol Obstet., 143, 385
Hasselaar P, 1990, J Rheumatol., 17, 186
Loizou S, 1985, Clin Exp Immunol., 62, 738
Ruiz-Arguelles G, 1989, J Rheumatol., 16, 381
McNeil H, 1990, Clin Exp Rheumatol., 8, 525

Sorted by citations

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · CHEST Journal · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,368
Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
Risk Factors for Venous Thromboembolism
Anderson, F. A., & Spencer, F. A. (2003) · Circulation · doi:10.1161/01.cir.0000078469.07362.e6 · Cited by 1,732
The Antiphospholipid Syndrome
Levine, J. S., Branch, D. W., & Rauch, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmra002974 · Cited by 1,524
Guidelines for the Primary Prevention of Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Goldstein, L. B., Bushnell, C. D., Adams, R. J., Appel, L. J., Braun, L. T., Chaturvedi, S., Creager, M. A., Culebras, A., Eckel, R. H., Hart, R. G., et al. (2011) · Stroke · doi:10.1161/str.0b013e3181fcb238 · Cited by 1,306
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 972
Guidelines for the Primary Prevention of Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Goldstein, L. B., Bushnell, C., Adams, R. J., Appel, L. J., Braun, L. T., Chaturvedi, S., Creager, M. A., Culebras, A., Eckel, R. H., Hart, R. G., et al. (2011) · Stroke · Cited by 745
Guidelines on the investigation and management of antiphospholipid syndrome
Keeling, D., Mackie, I., Moore, G. W., Greer, I. A., Greaves, M., & British Committee for Standards in Haematology (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09037.x · Cited by 740
Anticardiolipin Antibodies Predict Early Recurrence of Thromboembolism and Death Among Patients with Venous Thromboembolism Following Anticoagulant Therapy
Schulman, S., Svenungsson, E., & Granqvist, S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00060-6 · Cited by 497
Antiphospholipid Antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke
(2004) · JAMA · doi:10.1001/jama.291.5.576 · Cited by 478
Epidemiology of the Antiphospholipid Antibody Syndrome
Petri, M. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.2000.0409 · Cited by 468
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four‐year prospective study from the Italian Registry
Finazzi, G., Brancaccio, V., Moia, M., Ciavarella, N., Mazzucconi, M. G., Schinco, P., Ruggeri, M., Pogliani, E. M., Gamba, G., Rossi, E., et al. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00060-5 · Cited by 427
Antiphospholipid syndrome
Schreiber, K. I., Sciascia, S., de Groot, P. G., Devreese, K. M. J., Jacobsen, S., Ruiz‐Irastorza, G., Salmon, J. E., Shoenfeld, Y., Shovman, O., & Hunt, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.103 · Cited by 445
Activation of cultured vascular endothelial cells by antiphospholipid antibodies.
Simantov, R., Lasala, J. M., Lo, S. K., Gharavi, A. E., Sammaritano, L. R., Salmon, J. E., & Silverstein, R. L. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118276 · Cited by 420
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo controlled trial in asymptomatic antiphospholipid antibody-positive individuals.
Erkan, D., Harrison, M. J., Levy, R., Peterson, M., Petri, M., Sammaritano, L., Unalp‐Arida, A., Vilela, V., Yazici, Y., & Lockshin, M. D. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22663 · Cited by 401
Incidence of Venous Thromboembolism in Hospitalized Patients vs Community Residents
Heit, J. A., Melton, L. J., Lohse, C. M., Petterson, T. M., Silverstein, M. D., Mohr, D. N., & O’Fallon, W. M. (2001) · Mayo Clinic Proceedings · doi:10.4065/76.11.1102 · Cited by 375
Antiphospholipid Antibodies and venous thromboembolism
Ginsberg, J., Wells, P., Brill-Edwards, P., Donovan, D., Moffatt, K., Johnston, M., Stevens, P., & Hirsh, J. (1995) · Blood · doi:10.1182/blood.v86.10.3685.bloodjournal86103685 · Cited by 365
Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies
Tektonidou, M. G., Laskari, K., Panagiotakos, D. B., & Moutsopoulos, H. M. (2009) · Arthritis Care & Research · doi:10.1002/art.24232 · Cited by 356
Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein.
Hörkkö, S., Miller, E. R., Dudl, E. P., Reaven, P. D., Curtiss, L. K., Zvaifler, N., Terkeltaub, R. A., Pierangeli, S. S., Branch, D. W., Palinski, W., et al. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118854 · Cited by 348
A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome
Erkan, D. (2002) · Rheumatology · doi:10.1093/rheumatology/41.8.924 · Cited by 330
Antiphospholipid antibodies and thrombosis
Greaves, M. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10362-8 · Cited by 300
Guidelines On The Investigation and Management Of The Antiphospholipid Syndrome
Greaves, M., Cohen, H., Machin, S. J., & Mackie, I. J. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02069.x · Cited by 294
Prevalence, Follow-Up and Clinical Significance of the Anticardiolipin Antibodies in Normal Subjects
Vila, P., Hernández, M. C., Fernández, M. F. L., & Batlle, J. (1994) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648840 · Cited by 279
Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men.
Vaarala, O., Mänttäri, M., Manninen, V., Tenkanen, L., Puurunen, M., Aho, K., & Palosuo, T. (1995) · Circulation · doi:10.1161/01.cir.91.1.23 · Cited by 317
β 2 -Glycoprotein 1–Dependent Anticardiolipin Antibodies and Risk of Ischemic Stroke and Myocardial Infarction
Brey, R. L., Abbott, R. D., Curb, J. D., Sharp, D. S., Ross, G. W., Stallworth, C. L., & Kittner, S. J. (2001) · Stroke · doi:10.1161/01.str.32.8.1701 · Cited by 250
Thrombosis in primary antiphospholipid syndrome. A pivotal role for monocyte tissue factor expression
Cuadrado, M. J., López-Pedrera, C., Khamashta, M. A., Camps, M. T., Tinahones, F. J., Torres, A., Hughes, G. R. V., & Velasco, F. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400509 · Cited by 232
Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome
Pierangeli, S. S., Liu, X. W., Barker, J. H., Anderson, G., & Harris, E. N. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649940 · Cited by 223
Untitled work
(2004) · PubMed · Cited by 218
Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis
Arnaud, L., Mathian, A., Ruffatti, A., Erkan, D., Tektonidou, M., Cervera, R., Forastiero, R., Pengo, V., Lambert, M., Martinez-Zamora, M. A., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.10.014 · Cited by 215
IgG Anticardiolipin Antibody Titer >40 GPL and the Risk of Subsequent Thrombo-occlusive Events and Death
Levine, S. R., Salowich‐Palm, L., Sawaya, K. L., Perry, M., Spencer, H. J., Winkler, H. J., Alam, Z., & Carey, J. L. (1997) · Stroke · doi:10.1161/01.str.28.9.1660 · Cited by 212
The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus
Ünlü, O., Zuily, S., & Erkan, D. (2015) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2015.0085 · Cited by 212
Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients
Shah, N. M., Khamashta, M. A., Atsumi, T., & Hughes, G. R. (1998) · Lupus · doi:10.1191/096120398678919624 · Cited by 204
The geoepidemiology of the antiphospholipid antibody syndrome
Biggioggero, M., & Meroni, P. L. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.11.013 · Cited by 185
Prevention and Treatment of Venous Thromboembolism
Nicolaides, A. N., Fareed, J., Kakkar, A. K., Comerota, A. J., Goldhaber, S. Z., Hull, R. D., Myers, K. A., Samama, M. M., Fletcher, J., Kalodiki, E., et al. (2013) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612474840 · Cited by 187
Self-citation
Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study.
Ruffatti, A., Del Ross, T., Ciprian, M., Bertero, M. T., Salvatore, S., Scarpato, S., Montecucco, C., Rossi, S., Caramaschi, P., Biasi, D., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.142042 · Cited by 184
Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis
Wahl, D. G., Guillemin, F., de Maistre, E., Perret‐Guillaume, C., Lecompte, T., & Thibaut, G. (1998) · Lupus · doi:10.1191/096120398678919688 · Cited by 184
Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis
Matsuura, E., Kobayashi, K., TABUCHI, M., & LOPEZ, L. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.05.001 · Cited by 183
Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis
Reynaud, Q., Lega, J.-C., Mismetti, P., Chapelle, C., Wahl, D., Cathébras, P., & Laporte, S. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.11.004 · Cited by 179
‘Criteria’ aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010
Pierangeli, S., de Groot, P. G., Dlott, J. S., Favaloro, E. J., Harris, E., Lakos, G., Ortel, T. L., Meroni, P. L., Otomo, K., Pengo, V., et al. (2011) · Lupus · doi:10.1177/0961203310395055 · Cited by 179
The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus
McClain, M. T., Arbuckle, M. R., Heinlen, L. D., Dennis, G. J., Roebuck, J., Rubertone, M. V., Harley, J. B., & James, J. A. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20120 · Cited by 177
Does thrombophilia testing help in the clinical management of patients?
Middeldorp, S., & Vlieg, A. V. H. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07339.x · Cited by 177
Epidemiology and Etiology of Young Stroke
Griffiths, D., & Sturm, J. W. (2011) · Stroke Research and Treatment · doi:10.4061/2011/209370 · Cited by 179
Thrombogenicity of β2-glycoprotein I–dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster
Jankowski, M., Vreys, I., Wittevrongel, C., Boon, D., Vermylen, J., Hoylaerts, M., & Arnout, J. (2002) · Blood · doi:10.1182/blood-2002-05-1310 · Cited by 175
Epidemiology, Pathophysiology, Stratification, and Natural History of Pulmonary Embolism
Giordano, N. J., Jansson, P. S., Young, M. N., Hagan, K. A., & Kabrhel, C. (2017) · Techniques in vascular and interventional radiology · doi:10.1053/j.tvir.2017.07.002 · Cited by 171
Recurrent stroke and thrombo‐occlusive events in the antiphospholipid syndrome
Levine, S. R., Brey, R. L., Sawaya, K. L., Salowich‐Palm, L., Kokkinos, J., Kostrzema, B., Perry, M., Havstad, S. L., & Carey, J. (1995) · Annals of Neurology · doi:10.1002/ana.410380119 · Cited by 169
Central nervous system involvement in the antiphospholipid (Hughes) syndrome
Sanna, G. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg080 · Cited by 165
Diagnostic Testing for Coagulopathies in Patients With Ischemic Stroke
Bushnell, C., & Goldstein, L. B. (2000) · Stroke · doi:10.1161/01.str.31.12.3067 · Cited by 165
Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Streiff, M. B., Holmstrom, B., Angelini, D. E., Ashrani, A. A., Elshoury, A., Fanikos, J. R., Fertrin, K. Y., Fogerty, A. E., Gao, S., Goldhaber, S. Z., et al. (2021) · PubMed · doi:10.6004/jnccn.2021.0047 · Cited by 149
Self-citation
‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010
Bertolaccini, M. L., Amengual, O., Atsumi, T., Binder, W., de Laat, B., Forastiero, R. R., Kutteh, W. H., Lambert, M., Matsubayashi, H., Murthy, V. L., et al. (2011) · Lupus · doi:10.1177/0961203310397082 · Cited by 148
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients
Alén, J. C., Toloza, S., Fernández, M., Bastian, H. M., Fessler, B. J., Roseman, J. M., McGwin, G., Vilá, L. M., Reveille, J. D., Alarcón, G. S., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21149 · Cited by 147
The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation
Jennekens, F. G. I. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.6.619 · Cited by 147
Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model
Ferrara, D. E., Liu, X., Espinola, R. G., Meroni, P. L., Abukhalaf, I. K., Harris, E. N., & Pierangeli, S. S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11449 · Cited by 143
Antiphospholipid Antibodies and Stroke in Young Women
Brey, R. L., Stallworth, C. L., McGlasson, D. L., Wozniak, M. A., Wityk, R. J., Stern, B. J., Sloan, M. A., Sherwin, R. W., Price, T. R., Macko, R. F., et al. (2002) · Stroke · doi:10.1161/01.str.0000031927.25510.d1 · Cited by 141
Antiphospholipid-protein antibodies: Laboratory detection and clinical relevance
Triplett, D. A. (1995) · Thrombosis Research · doi:10.1016/0049-3848(95)00001-1 · Cited by 125
Elevated Anticardiolipin Antibody Titer Is a Stroke Risk Factor in a Multiethnic Population Independent of Isotype or Degree of Positivity
Tuhrim, S., Rand, J. H., Wu, X.-X., Weinberger, J. M., Horowitz, D. R., Goldman, M. E., & Godbold, J. (1999) · Stroke · doi:10.1161/01.str.30.8.1561 · Cited by 123
Autoantibodies Against Oxidized Low-Density Lipoprotein and Cardiolipin in Patients With Coronary Heart Disease
Erkkilä, A. T., Närvänen, O., Lehto, S., Uusitupa, M. I. J., & Ylä‐Herttuala, S. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.1.204 · Cited by 122
Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model.
Ziporen, L., Shoenfeld, Y., Levy, Y. M., & Korczyn, A. D. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119572 · Cited by 117
Baseline Disease Activity, Hyperlipidemia, and Hypertension Are Predictive Factors for Ischemic Stroke and Stroke Severity in Systemic Lupus Erythematosus
Mikdashi, J. A., Handwerger, B. S., LANGENBERG, P. W., Miller, M. J., & Kittner, S. J. (2007) · Stroke · doi:10.1161/01.str.0000254476.05620.14 · Cited by 117
Anticardiolipin Antibodies and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Cohort and Offspring Study
Janardhan, V., Wolf, P. A., Kase, C. S., Massaro, J. M., D’Agostino, R. B., Franzblau, C., & Wilson, P. W. F. (2004) · Stroke · doi:10.1161/01.str.0000117575.48205.2d · Cited by 116
Neurological manifestations of antiphospholipid antibody syndrome
Brey, R. L., & Escalante, A. (1998) · Lupus · doi:10.1177/096120339800700216 · Cited by 114
Antiphospholipid Syndrome during pregnancy: the state of the art.
Prima, F. A. F. D., Valenti, O., Hyseni, E., Giorgio, E., Faraci, M., Renda, E., Domenico, R. D., & Monte, S. (2011) · PubMed Central · Cited by 111
Antiphospholipid syndrome as the second cause of non-tumorous Budd-Chiari syndrome
Pelletier, S., Landi, B., Pietté, J. C., Ekert, P., Coutellier, A., Desmoulins, C., Fadlallah, J.-P., Herson, S., & Valla, D. C. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(94)80140-1 · Cited by 113
PATHOGENESIS AND TREATMENT OF THE ANTIPHOSPHOLIPID ANTIBODY SYNDROME
Petri, M. (1997) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70509-5 · Cited by 112
Anticardiolipin antibodies in an unselected stroke population
Muir, K. W., Squire, I. B., Lees, K. R., & Alwan, W. H. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91775-2 · Cited by 109
THE LUPUS ANTICOAGULANT/ANTIPHOSPHOLIPID SYNDROME
Shapiro, S. S. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.533 · Cited by 107
Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study
Ruffatti, A., Ross, T. D., Ciprian, M., Nuzzo, M., Rampudda, M., Bertero, M. T., Bergia, R., Caramaschi, P., Biasi, D., Capsoni, F., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.096669 · Cited by 106
A protocol for determination of anticardiolipin antibodies by ELISA
Pierangeli, S. S., & Harris, E. N. (2008) · Nature Protocols · doi:10.1038/nprot.2008.48 · Cited by 106
Antiphospholipid syndrome
Petri, M. (2020) · Translational research · doi:10.1016/j.trsl.2020.04.006 · Cited by 113
Prophylaxis of the antiphospholipid syndrome: a consensus report
Alarcón-Segovia, D., Boffa, M., Branch, W. D., Cervera, R., Gharavi, A. E., Khamashta, M. A., Shoenfeld, Y., Wilson, W., & Roubey, R. A. S. (2003) · Lupus · doi:10.1191/0961203303lu388oa · Cited by 99
Cerebral Manifestations in the Antiphospholipid (Hughes) Syndrome
Sanna, G., D’Cruz, D. P., & Cuadrado, M. J. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.05.010 · Cited by 95
From antiphospholipid syndrome to antibody-mediated thrombosis
Roubey, R. A. S., & Hoffman, M. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63936-0 · Cited by 96
Antiphospholipid Antibodies in Retinal Vascular Occlusions
Glacet-Bernard, A. (1994) · Archives of Ophthalmology · doi:10.1001/archopht.1994.01090180088041 · Cited by 95
The Clinical Presentation of Systemic Lupus Erythematosus
Lahita, R. G. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-374994-9.10030-0 · Cited by 93
Laboratory diagnosis of the antiphospholipid syndrome
Wislöff, F., Jacobsen, E. M., & Liestøl, S. (2002) · Thrombosis Research · doi:10.1016/s0049-3848(02)00400-0 · Cited by 92
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)
Cuadrado, M. J., Bertolaccini, M. L., Seed, P. T., Tektonidou, M. G., Aguirre, A., Micó, L., Gordon, C., Ruiz‐Irastorza, G., Egurbide, M.-V., Gil, A., et al. (2013) · Rheumatology · doi:10.1093/rheumatology/ket313 · Cited by 92
Primary Anti-Phospholipid Antibody Syndrome (APS)
Durrani, O. M., Gordon, C., & Murray, P. I. (2002) · Survey of Ophthalmology · doi:10.1016/s0039-6257(02)00289-8 · Cited by 90
Anti-Cardiolipin Antibodies in Patients with Inflammatory Bowel Disease
Aichbichler, B. W., Petritsch, W., Reicht, G., Wenzl, H., Eherer, A. J., Hinterleitner, T. A., Auer‐Grumbach, P., & Krejs, G. J. (1999) · Digestive Diseases and Sciences · doi:10.1023/a:1026646816672 · Cited by 90
High Prevalence of Antiphosphatidylinositol Antibodies in Young Patients With Cerebral Ischemia of Undetermined Cause
Toschi, V., Motta, A., Castelli, C., Paracchini, M. L., Zerbi, D., & Gibelli, A. (1998) · Stroke · doi:10.1161/01.str.29.9.1759 · Cited by 89
Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture*
Lowe, G. D. O. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06021.x · Cited by 86
Anticardiolipin Antibodies Are Not an Independent Risk Factor for Stroke
Ahmed, E., Stegmayr, B., Trifunovic, J., Weinehall, L., Hallmans, G., & Lefvert, A. K. (2000) · Stroke · doi:10.1161/01.str.31.6.1289 · Cited by 88
Comparison of characteristics from White‐ and Black‐Americans with venous thromboembolism: A cross‐sectional study
Heit, J. A., Beckman, M. G., Bockenstedt, P. L., Grant, A. M., Key, N. S., Kulkarni, R., Manco‐Johnson, M. J., Moll, S., Ortel, T. L., & Philipp, C. S. (2010) · American Journal of Hematology · doi:10.1002/ajh.21735 · Cited by 86
Predicting and Preventing Autoimmunity, Myth or Reality?
Harel, M., & Shoenfeld, Y. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1351.031 · Cited by 84
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients
Hereng, T., Lambert, M., HACHULLA, E., Samor, M., Dubucquoi, S., Caron, C., Launay, D., Morell‐Dubois, S., Queyrel, V., & Hatron, P. (2007) · Lupus · doi:10.1177/0961203307084724 · Cited by 84
Anti-cardiolipin and Anti-β2-glycoprotein I Antibodies in Patients with Inflammatory Bowel Disease
Κoutroubakis, I. E., Petinaki, E. A., Anagnostopoulou, E., Kritikos, H. D., Mouzas, I., Kouroumalis, E., & Manousos, O. N. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1026602803622 · Cited by 84
Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002
Brey, R. L., Chapman, J., Levine, S. R., Ruiz‐Irastorza, G., Derksen, R. H. W. M., Khamashta, M. A., & Shoenfeld, Y. (2003) · Lupus · doi:10.1191/0961203303lu390oa · Cited by 82
Risk factors for microangiopathy-related cerebral damage in the Austrian stroke prevention study
Schmidt, R., Fazekas, F., Hayn, M., Schmidt, H., Kapeller, P., Roob, G., Offenbacher, H., Schumacher, M., Eber, B., Weinrauch, V., et al. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00137-8 · Cited by 82
Venous Thrombosis in the Antiphospholipid Syndrome
Farmer-Boatwright, M. K., & Roubey, R. A. S. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.182204 · Cited by 82
Cerebral magnetic resonance imaging in patients with or without antiphospholipid antibodies
HACHULLA, E., Michon-Pasturel, U., Leys, D., Pruvo, J., Queyrel, V., Masy, E., Arvieux, J., Caron, C., Brevet, F., Hatron, P., et al. (1998) · Lupus · doi:10.1191/096120398678919868 · Cited by 81
Management of antiphospholipid syndrome
Tuthill, J. I., & Khamashta, M. A. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.05.002 · Cited by 78
Pulmonary embolism: the diagnosis, risk-stratification, treatment and disposition of emergency department patients
Corrigan, D., Prucnal, C. K., & Kabrhel, C. (2016) · Clinical and Experimental Emergency Medicine · doi:10.15441/ceem.16.146 · Cited by 83
Antiphospholipid syndrome
Gezer, S. (2003) · Disease-a-Month · doi:10.1016/j.disamonth.2003.10.001 · Cited by 81
Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis
Prakash, R., Miller, C. C., & Suki, W. N. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90656-8 · Cited by 80
Coronary artery disease in systemic lupus erythematosus: A review of the literature
Karrar, A., Sequeira, W., & Block, J. A. (2001) · Seminars in Arthritis and Rheumatism · doi:10.1053/sarh.2001.23498 · Cited by 79
Anti-b 2 -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With Antiphospholipid Syndrome
Lopez, L. R., Dier, K. J., Lopez, D., Merrill, J. T., & Fink, C. (2004) · American Journal of Clinical Pathology · doi:10.1309/yvq6-px76-xmym-3j29 · Cited by 79
Which are the Best Biological Markers of the Antiphospholipid Syndrome?
Carreras, L. O., Forastiero, R. R., & Martinuzzo, M. E. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.2000.0401 · Cited by 78
The antiphospholipid and thrombosis syndromes
Bick, R. L., & Baker, W. (1994) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30152-3 · Cited by 78
Assessing the Usefulness of Anticardiolipin Antibody Assays
Favaloro, E. J., & Silvestrini, R. A. (2002) · American Journal of Clinical Pathology · doi:10.1309/jamh-gdq6-6byk-dw6j · Cited by 78
Real world experience with antiphospholipid antibody tests: how stable are results over time?
Erkan, D., Derksen, W. J. M., Kaplan, V, Sammaritano, L., Pierangeli, S. S., Roubey, R., & Lockshin, M. D. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.031856 · Cited by 76
Anticardiolipin Antibodies and Recurrent Coronary Events
Bili, A., Moss, A. J., Francis, C. W., Zaręba, W., Watelet, L. F. M., Sanz, I., Factors, F. T. T., & Recurrent Coronary Events Investigators (2000) · Circulation · doi:10.1161/01.cir.102.11.1258 · Cited by 76

Authors: Ginsburg, K. S., Liang, M. H., Newcomer, L., Goldhaber, S. Z., Schur, P. H., Hennekens, C. H., & Stampfer, M. J.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Liang, Matthew H.
Goldhaber, Samuel Z.
Hennekens, Charles H.
Stampfer, Meir J.
Venue: Annals of Internal Medicine
Publisher: American College of Physicians
Published: 1992-12-15
Volume: 117
Issue: 12
Pages: 997-1002
ISSN: 0003-4819 (ISSN-L)
1539-3704
DOI: 10.7326/0003-4819-117-12-997
OpenAlex: W1491481195
Cited by: 526
References: 49
Citations by year: 2025: 2 · 2024: 7 · 2023: 5 · 2022: 1 · 2021: 8 · 2020: 8 · 2019: 4 · 2018: 3 · 2017: 6 · 2016: 7 · 2015: 7 · 2014: 10 · 2013: 15 · 2012: 16
FWCI: 16.25
Type: journal article
Language: en
Open access: closed
Locations: Annals of Internal Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (R01CA042182, CA 42182)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (P60AR036308, AR-36308, AR-07530, T32AR007530)
Topics: Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords: anticardiolipin antibodies, ischemic stroke, venous thrombosis, deep vein thrombosis, pulmonary embolism, thrombophilia, risk factors, IgG, male physicians, Physicians' Health Study, aspirin, beta-carotene, anticoagulation, stroke prevention, antithrombotic therapy
MeSH terms: Adult, Aged, Aged, 80 and over, Brain Ischemia, Enzyme-Linked Immunosorbent Assay, Humans, Male, Middle Aged, Prospective Studies, Pulmonary Embolism, Risk Factors, Statistics as Topic, Thrombophlebitis, Case-Control Studies, Antibodies, Anticardiolipin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Anticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous Thrombosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks